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Ambulatory consolidation chemotherapy for
acute myeloid leukemia with antibacterial
prophylaxis is associated with frequent
bacteremia and the emergence of
fluoroquinolone resistant E. Coli
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Abstract
Background: Ambulatory consolidation chemotherapy for acute myeloid leukemia (AML) is frequently associated
with bloodstream infections but the spectrum of bacterial pathogens in this setting has not been well-described.
Methods: We evaluated the emergence of bacteremias and their respective antibiotic susceptibility patterns in AML
patients receiving ambulatory-based consolidation therapy. Following achievement of complete remission, 207
patients received the first cycle (C1), and 195 the second cycle (C2), of consolidation on an ambulatory basis.
Antimicrobial prophylaxis consisted of ciprofloxacin, amoxicillin and fluconazole.
Results: There were significantly more positive blood cultures for E. coli in C2 as compared to C1 (10 vs. 1,
p=0.0045); all E. coli strains for which susceptibility testing was performed demonstrated resistance to ciprofloxacin.
In patients under age 60 there was a significantly higher rate of Streptococccus spp. bacteremia in C2 vs. C1; despite
amoxicillin prophylaxis all Streptococcus isolates in C2 were sensitive to penicillin. Patients with Staphylococcus
bacteremia in C1 had significantly higher rates of Staphylococcus bacteremia in C2 (p=0.009, OR=8.6).
Conclusions: For AML patients undergoing outpatient-based intensive consolidation chemotherapy with antibiotic
prophylaxis, the second cycle is associated with higher rates of ciprofloxacin resistant E. coli, penicillin-sensitive
Streptococcus bacteremias and recurrent Staphylococcus infections.
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Background
Intensive treatment for acute myeloid leukemia (AML)
typically includes induction followed by 2–4 cycles of
consolidation chemotherapy [1]. In recent years there
has been a shift to outpatient-based AML consolidation
therapy with a number of studies confirming the safety
of this approach for selected patients [2-9].
In most centers ambulatory chemotherapy programs
rely on the use of antimicrobial prophylaxis as a means
of reducing infections. Recent Infectious Disease Society
of America (IDSA) guidelines endorse the use of cipro-
floxacin prophylaxis to reduce bacterial infections in
high risk cancer patients receiving chemotherapy [10].
Despite prophylactic antibiotics 30-90% of ambulatory
patients experience a fever and 20-90% of consolidation
cycles are associated with hospitalizations [2,4-6]. How-
ever, there are limited data on the characteristics of
infectious complications in this setting. We have pre-
viously shown that infectious complications increase in
the second cycle of ambulatory AML consolidation
therapy resulting in greater need for intensive care unit
(ICU) support and increased mortality [11]. As these
findings may relate to breakthrough infections caused by
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the development of antibiotic resistant microbes despite
prophylactic antibiotic use, we conducted a retrospective
analysis evaluating the spectrum of microbiological isolates
and their antibiotic resistance patterns in AML patients
undergoing ambulatory-based consolidation chemotherapy.
Methods
Patients
All newly diagnosed AML patients at the Princess
Margaret Hospital (PMH) who had achieved complete
remission with frontline induction chemotherapy and
proceeding to ambulatory-based consolidation chemo-
therapy from October 2002 - February 2008 were in-
cluded in the analysis. Eligibility requirements were as
previously described [11]. Patients received the second
consolidation cycle following peripheral count recovery
from the first cycle and resolution of any previous bacte-
rial infections. Prior approval for the study was obtained
from the Cancer Registry Data Access Committee and
Research Ethics Board of the University Health Network,
Toronto, Ontario.
Chemotherapy regimens and supportive care
Ambulatory chemotherapy, subsequent monitoring and
supportive care were provided as previously described
[11] either in the ambulatory care area of the PMH or a
local community hospital/clinic. Patients under age 60
(younger cohort) received two cycles of consolidation
therapy (C1 and C2), each consisting of high dose
cytarabine (HiDAC) 3 grams/m2 IV q12 hours × 6 doses
on days 1, 3, and 5, plus daunorubicn 45 mg/m2 IV daily
on days 1 and 2. For patients over age 60 (older cohort),
C1 consisted of daunorubicin 60 mg/m2 IV daily × 3
plus cytarabine 100 mg/m2 as a 7-day continuous infu-
sion via ambulatory infusion pump and C2 consisted of
mitoxantrone 10 mg/m2 IV plus etoposide 100 mg/m2
IV, each given once daily from days 1–5.
During induction therapy patients received antimicro-
bial prophylaxis with fluconazole 400 mg PO daily
whereas during consolidation they received ciprofloxacin
500 mg PO q12 hours, amoxicillin 500 mg PO q8 hours
and fluconazole 400 mg PO daily, starting on Day 8 of the
chemotherapy cycle and continuing until absolute neutro-
phil count (ANC) > 0.5 × 109/L. All chemotherapy, trans-
fusions and IV antibiotics were administered via central
venous catheters (CVC), usually double lumen Hickman
lines placed prior to the start of induction chemotherapy.
Patients presenting with fever or clinical features of an
infection had blood cultures drawn from all CVC ports,
a peripheral vein and any other accessible sites suspected
of being infected. As per institutional policy, empiric anti-
biotics for febrile neutropenia most commonly consisted
of pipracillin/tazobactam 4.5 grams IV q8 hours plus
tobramycin 5 mg/kg IV q24 hours. Febrile patients with
suspected CVC involvement i.e. those with erythema, pain
or purulent drainage at the insertion site, were started on
vancomycin 1 gram IV q12 hours. Empiric therapy was
adjusted based upon the results of culture and sensitivity
testing. Antimicrobials were continued until microbio-
logical and clinical evidence of infection had resolved and
the ANC was > 0.5 × 109/L. Hematopoietic growth factors
were not routinely used but were administered at the phy-
sician’s discretion from day 16–18 until neutrophil reco-
very. Patients with blood cultures positive for coagulase
negative staphylococci (CNST) usually retained their CVC
whereas patients with candidemia, tunnel infections or
those with persistently positive cultures beyond 72 hours
had their CVC replaced.
Cultures were processed using standard microbiological
methods. Antibiotic susceptibilities were performed and
reported by the Department of Microbiology of the Mount
Sinai Hospital/University Health Network (Toronto,
Ontario) or the local community hospital (if the site of
the patient’s initial presentation) using predefined cri-
teria. Antibiotic sensitivity data were not available in
some cases where patients presented to local commu-
nity hospitals.
Definitions
Blood cultures were considered positive if one or more
culture bottles showed growth, regardless of the organ-
ism, with symptoms compatible with an infection. Bac-
teremias related to common contaminants such as
CNST, Micrococcus., Propionibacterium or Bacillus spp.
were treated with a full course of antibiotics; thus no
distinction was made between contaminants and true
pathogens. Cultures were considered polymicrobial if at
least two different organisms were isolated. Repeated
cultures in persistently febrile patients yielding the same
organism with the same antibiotic susceptibility profile
were considered as one isolate unless separated by one
or more negative blood cultures.
Statistical analysis
Descriptive statistics were used to describe patient char-
acteristics and outcome recordings. Categorical variables
were expressed as count and proportions whereas con-
tinuous variables were expressed as means. Pearson Chi-
square or Fisher’s exact test, when applicable, were used
when comparing rates of infection and readmission.
Results were considered significant if two-tailed P was
< 0.05. Statistical Analysis Software (SAS, version 9.2; SAS
Institute Inc., Cary NC) was used for statistical analysis.
Results
Patient characteristics
The characteristics of the patients receiving ambulatory-
based consolidation chemotherapy have been previously
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described [11], and are summarized in Table 1. There
was no significant difference in the median age of pa-
tients between C1 and C2; 54.6% of patients in C1 and
52.3% in C2 were male and the proportion of patients
age ≥ 60 was 30% in C1 and 33% in C2 (p=NS).
Bacteremia during ambulatory chemotherapy
Microbiologically documented episodes of bacteremia
are shown in Table 1. As we previously reported, the
ambulatory cohort in C2 had significantly higher rates of
positive blood cultures and bloodstream infection rela-
tive to C1 [11]. Most patients had only a single positive
blood culture (86% in C1 and 90% in C2) with greater
than 90% of cultures in each cycle being monomicrobial.
In each consolidation cycle significantly more patients
had a gram-positive bacterial infection as compared to
gram-negative infections. The proportion of gram posi-
tive vs. gram negative isolates was not significantly dif-
ferent in C1 as compared to C2. Approximately 30% of
patients presented to local community hospitals, where
the source of the positive blood culture (CVC vs. per-
ipheral) was not identified; we were therefore unable to
determine the extent of CVC related bacteremias in
these cases.
As shown in Table 1, CNST were the most common
gram positive isolates during both cycles. Streptococci
constituted 17% (9/53) of the total isolates in C1 and
23.9% (17/71) of the total isolates in C2 (p=0.35). Youn-
ger patients had a significantly higher incidence of
streptococcal bacteremia in C2 relative to C1 (11.2% vs.
4.3%, p=0.033), and in these patients streptococci repre-
sented a greater proportion of the total isolates in C2
(34%, 15/44 isolates) relative to C1 (15%, 6/40 isolates,
p=0.044).
Gram negative organisms were identified in 5.6% of
patients in C1 vs. 10.7% of those in C2 (p=0.07). The fre-
quency of E. coli isolates was significantly higher in C2
relative to C1 (5.4% vs. 0.5%, p=0.005) with E. coli consti-
tuting 14.1% (10/71) of all isolates in C2 and 1.9% (1/53)
of those in C1 (p=0.023). This trend was observed in
both the younger (0 in C1 vs. 4 in C2) and older (1 in
C1 vs. 6 in C2) cohorts. In addition, there was no differ-
ence in the incidence of E. coli bacteremia in younger
versus older patients within C1 (p=0.827) or C2 (p=0.8).
The proportion of patients with non-E. coli gram nega-
tive isolates did not differ between C1 and C2 (5.1% vs.
5.3%, p=0.91).
Antibiotic resistance patterns
Table 2 highlights the antibiotic resistance patterns for se-
lected organisms. Only one of the CNST with antibiotic
sensitivity data was resistant to vancomycin while virtually
all isolates were resistant to cloxacillin. All Streptococcus
spp. isolates with susceptibility data exhibited sensitivity to
penicillin. Among the non- E. coli gram-negative isolates,
there was no difference in rates of ciprofloxacin resistance
between C1 and C2 (1/9 vs. 0/7, p=1.0). In contrast, all
E. coli isolates (8/8) from patients in C2 for which suscep-
tibilities were available were ciprofloxacin resistant.
As shown in Table 2, most gram negative isolates in
C1 and C2 were sensitive to the commonly used empiric
antibiotics for febrile neutropenia in our institution,
piperacillin/tazobactam and aminoglycosides. However,
tobramycin resistance was noted in 67% (4/6) of the
E. coli isolates, including 3/5 isolates from patients in C2.
Infection-related mortality
Overall, 9 patients died due to infectious complications
while receiving ambulatory chemotherapy, one patient
during C1 and 8 during C2. CNST were isolated from
one such patient during C2 whereas Streptococcus spp.
was isolated from two patients who died (one each in C1
and C2). The single Streptococcus isolate with available
antibiotic susceptibility information was sensitive to
penicillin and vancomycin. Gram negative organisms
were isolated in 6 of the 8 patient deaths in C2: Klebsi-
ella spp. (3 cases), E. coli (2) and Pseudomonas spp. (1,
urine isolate). Both E. coli isolates were resistant to cip-
rofloxacin and tobramycin and displayed sensitivity only
to piperacillin/tazobactam. Mortality amongst patients
with ciprofloxacin resistant gram-negative bacteremias
was 20% (2/10) versus 13.3% (2/15) for those with cipro-
floxacin sensitive strains (p=1.0).
Effect of previous positive cultures/hospitalization
Approximately 51% of patients with a positive blood
culture in C1 had a subsequent positive culture in C2
while only 27% of those with negative blood cultures in
C1 had a positive culture in C2 (OR=2.8, p=0.005). This
trend was significant for gram-positive organisms
(OR=3.25, p=0.004) but not for gram-negative organ-
isms (OR=2.1, p=0.31). An infection with Staphylococ-
cal isolates in C1 was associated with the highest
recurrence rates in C2 but only for patients age <60
(OR=8.6, p=0.009). No such association was seen for
Streptococcal isolates or in the older cohort.
Discussion
Recent data suggest that ambulatory chemotherapy for
AML patients can reduce the incidence of septicemia
[7]. However, published data on the characteristics of
microbiological isolates from patients receiving ambula-
tory chemotherapy remains limited [2-7,9]. Our study,
focusing on bacterial bloodstream infections, represents
the largest reported series on AML patients receiving
ambulatory-based intensive consolidation chemotherapy.
We have previously shown that the rate of positive blood
cultures increases following the second consolidation
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Table 1 Blood culture results
C#1 C#2 (p-value)
Total Number of Patients 196 187
Age < 60 140 126
Age ≥ 60 56 61
% Male 107 (54.6%) 98 (52.3%)
At least one blood culture positive (% of patients) 43 (21.9%) 59 (31.6%) P=0.03
1 culture positive 37 (86%) 53 (90%) NS
2 or more cultures positive 6 (14%) 6 (10%) NS
Patients with Gram Positive isolates (% of Patients) 35 (17.9%) 46 (24.6%) 0.11
Patients with Gram Negative isolates (% of patients) 11 (5.6%) 20 (10.7%) 0.07
Gram Positive vs. Gram Negative P=0.0002 P=0.0004
Total number of positive blood cultures: 49 65
Monomicrobial cultures (% of total cultures) 45 (91.8%) 60 (92.3%) NS
Polymicrobial cultures (% of total cultures) 4 (8.2%) 5 (7.7%) NS
Total number of isolates: 53 71
Age < 60 40 44
Age ≥ 60 13 27
Clinical Isolates (% of patients)
Gram Positive+ 35 (17.9%) 46 (24.6%) P=0.10
CNST* 19 (9.7%) 23 (12.4%) NS
Corynebacterium 5 (2.6%) 2 (1.1%)
Micrococcus 4 (2.0%)
Enterococcus 1 (0.5%) 3 (1.6%)
Staphyloccoccus. aureus 2 (1.0%) 1 (0.5%)
Streptococcus species 9 (4.6%) 16 (8.6%) P=0.11
Streptococcus viridins 6 (3.1%) 13 (7.0%)
Streptococcus viridians/Streptococcus oralis - 1 (0.5%)
Streptococcus mitis 2 (1.0%) -
Streptococcus auralis - 1 (0.5%)
Streptococcus spp. 1 (0.5%) 1 (0.5%)
< age 60 with Strep. 6 (4.3%) 14 (11.2%) P=0.033
≥ age 60 with Strep. 3 (5.36%) 2 (3.3%) NS
Other Gram Positive 1 (0.5%) 4 (2.1%)
Gram Negative 11 (5.6%) 20 (10.7%) P=0.07
Age < 60 8 (5.7%) 9 (7.1%) NS
Age ≥ 60 3 (5.4%) 11 (18%) P=0.035
Eschericia coli 1 (0.5%) 10 (5.3%) P=0.005
Klebsiella 2 (1.0%) 5 (2.7%)
Enterobacter 3 (1.5%) 1 (0.5%)
Pseudomonas spp. 4 (2.0%) -
Other Gram Negative 1 (0.5%) 4 (2.1%)
Yeast - 1 (0.5%)
CNST* = coagulase-negative staphylococci;
Gram Positive+ = Species information available for 185 pts. in C2 (Age < 60=125, Age ≥ 60=65).
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cycle [11] and the current study highlights potential ex-
planations for the observed increase.
Despite the isolation of ciprofloxacin resistant E. coli
in febrile neutropenic patients receiving fluoroquinolone
prophylaxis [7,12,13] their use in high risk patients re-
ceiving chemotherapy has been supported by large ran-
domized clinical trials and meta-analysis [14-17]. Within
our cohort we observed an increased incidence of gram-
negative bacteremia and ciprofloxacin resistance as
patients transitioned from C1 to C2. Ciprofloxacin re-
sistance was observed in 100% of the E. coli strains in
C2, was rarely seen in Pseudomonas spp (1/4 in C1) and
was not observed in the remaining Enterobacteriaceae
(0/5 in C1 and 0/7 in C2). The preferential development
of resistance among E. coli strains has been previously
reported [18-20]. Cometta et al. noted that, among a co-
hort of patients receiving prophylactic fluoroquinolones,
28% of the E. Coli isolates were fluoroquinolone resistant
while > 90% of the P. aeruginosa and K. pneumoniae
isolates remained fluoroquinolone sensitive [18]. Kern
et al. postulated the decreased virulence of fluoroquino-
lone resistant P. aeruginosa as one explanation for this
phenomenon [20]. Prolonged exposure to subtherapeutic
concentrations of antibiotics has been associated with
the development of antibiotic resistance [21,22]. It is
possible that decreased absorption of fluoroquinolones
in the setting of chemotherapy-induced mucositis, may
have prevented reaching the mutant prevention concen-
tration [23,24] for E. coli in our cohort. We were unable
to determine whether there was an emergence of resist-
ance to other antibiotics, although the frequency of E. coli
aminoglycoside resistance in C2 (4/6 cases) is concerning.
The effects of discontinuing prophylactic fluoroquino-
lones have been investigated in a number of studies.
Reuter et al. prematurely stopped a trial of levofloxacin
discontinuation due to a significant increase in infection-
related mortality [25] and Kern et al. noted increased rates
of bacteremia and a trend toward increased mortality dur-
ing a period in which fluoroquinolone prophylaxis was
discontinued [12]. A similar increase in bloodstream infec-
tions with fluoroquinolone susceptible isolates was seen
when fluoroquinolone prophylaxis was discontinued by
two Japanese groups although no effects on mortality were
noted [26,27]. Thus, although the emergence of cipro-
floxacin resistance organisms calls into question the
value of ciprofloxacin prophylaxis, current evidence and
IDSA guidelines support its use in high-risk patients
with prolonged (≥ 7 days) and profound neutropenia
(≤100 cells/mm3) [10].
The increased use of fluoroquinolone prophylaxis and
indwelling CVC’s has led to gram-positive organisms as
the main cause of bacteremia in immunocompromised
patients [4,6,7,28]. In our cohort gram-positive organ-
isms constituted 79% of the isolates during C1 and 70%
in C2. As some of our patients were followed in commu-
nity hospitals, we were unable to accurately determine
which isolates were CVC related although we speculate
that most CNST were of CVC origin. Consistent with
previous reports [2,6,7,28,29], CNST and Streptococcus
spp. were the most common gram positive organisms.
The rate of CNST isolates was not statistically different
between C1 and C2, however, Streptococcus isolates, par-
ticularly S. viridans, increased from C1 to C2 within the
younger cohort, likely reflecting the cumulative effects
of HiDAC chemotherapy [11,28,30-32].
As a high frequency of S. viridans infections is a well-
documented effect associated with ciprofloxacin prophy-
laxis [12], patients within our cohort were administered
amoxicillin during the neutropenic period. Surprisingly,
Table 2 Antibiotic resistance patterns of isolates (number
showing resistance / isolates with antibiotic sensitivity
data available)
Consolidation 1 Consolidation 2
(% of isolates) (% of isolates)
CNST 20 (37.7%) 23 (32.4%)
Vancomycin resistant 1 / 15 0 / 21
Cloxacillin resistant 14 / 17 21 / 22
Streptococcus species 9 (17%) 17 (23.9%)
Penicillin resistant 1 / 7 0 / 11
Vancomycin resistant 0 / 3 0 / 6
Gram Negatives 11 (20.7%) 20 (28.1%)
Ciprofloxacin resistant 2 / 10 8 / 15
P/T* resistant 1 / 10 0 / 14
Ampicillin resistant 9 / 9 13 / 15
Tobramycin resistant 1 / 8 3 / 10
Klebsiella species 2 (3.8%) 5 (7.0%)
Ciprofloxacin resistant 0/2 0 / 4
P/T* resistant 0/2 0 / 4
Ampicillin resistant 2/2 4 / 4
Tobramycin resistant 0/2 0 / 3
Escherichia coli 1 (1.9%) 10 (14.1%)
Ciprofloxacin resistant 1/1 8 / 8
P/T* resistant 0 / 1 0 / 8
Ampicillin resistant 1 / 1 7 / 8
Tobramycin resistant 1/1 3 / 5
Pseudomonas species 4 (7.6%) -
Ciprofloxacin resistant 1 / 4 -
P/T* resistant 1/1 -
Ampicillin resistant 3/3 -
Tobramycin resistant 0 / 4 -
*P/T = Piperacillin/tazobactam.
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however, all Streptococcus isolates with susceptibility data
were found to be penicillin sensitive. Poor compliance
with amoxicillin dosing or prior CVC colonization may
provide a potential explanation for this observation. Al-
though current IDSA guidelines recommend against the
addition of gram-positive coverage to fluoroquinolone
prophylaxis, studies have suggested that it may be benefi-
cial in patients at high risk of streptococcal infections
including those with severe neutropenia, oral mucositis,
bone marrow transplantation and those receiving HiDAC-
based chemotherapy [33]. From our data, it is unclear if
the addition of amoxicillin alone resulted in any substan-
tial benefit; delineation of this would require a prospective
randomized study.
An important finding in our study, not previously de-
scribed, is the increased rate of positive blood cultures
in C2 in patients with previous positive cultures in C1.
This effect was restricted to Staphylococcus spp. in youn-
ger patients and may reflect the prolonged use of indwell-
ing catheters. The inadequate activity of ciprofloxacin and
amoxicillin against these organisms likely further contrib-
uted to their increased pathogenicity [14,29]. It is possible
that CVC replacement between consolidation cycles in
patients previously positive for Staphylococcus spp. could
reduce their recurrence rates, but this requires further
study.
Our data have several limitations. This was a retrospect-
ive analysis conducted at a single tertiary care cancer cen-
ter and it is unclear whether results are generalizable to
other centers or with different regimens. Second, our rates
of gram-positive bacteremia may have been overestimated
as we could not always accurately differentiate whether
isolates represented true bacteremia, CVC colonization or
contamination. However, given the context of fever in
high-risk neutropenic patients, all of whom were treated
empirically with IV antibiotics, infection is more likely.
Furthermore, as some patients were treated in community
hospitals, we had incomplete information regarding anti-
biotic sensitivities.
Conclusions
In summary, our findings emphasize the limitations of anti-
bacterial prophylaxis of AML patients post-chemotherapy
in the ambulatory setting, particularly in later cycles follow-
ing prolonged use of fluoroquinolones and indwelling
central venous catheters. Clinicians should be cognizant of
the resulting increased predilection to fluoroquinolone-
resistant E. coli, streptococcal spp. and recurrent CNST
infections, and additional prophylactic measures should be
considered in these patients.
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